A Study to Evaluate the Efficacy & Safety of Recombinant Human Growth

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05328050` - Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Completed	`NCT05659719` - A Study to Learn About Recifercept in Patients With Achondroplasia
Active, not recruiting	`NCT04554940` - A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia	Phase 2
Completed	`NCT01435629` - A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin	N/A
Enrolling by invitation	`NCT06164951` - A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia	Phase 3
Completed	`NCT01516229` - Special Survey for Long Term Application	N/A
Completed	`NCT03872531` - Lifetime Impact Study for Achondroplasia
Active, not recruiting	`NCT05598320` - A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia	Phase 2/Phase 3
Terminated	`NCT05813314` - Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants	Phase 1
Recruiting	`NCT04265651` - Study of Infigratinib in Children With Achondroplasia	Phase 2
Recruiting	`NCT05603936` - Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
Completed	`NCT03780153` - The Norwegian Adult Achondroplasia Study
Active, not recruiting	`NCT04085523` - A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia	Phase 2
Enrolling by invitation	`NCT05929807` - A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia	Phase 2/Phase 3
Not yet recruiting	`NCT06433557` - A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia	Phase 2
Completed	`NCT03875534` - A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
Terminated	`NCT03794609` - Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
Completed	`NCT03583697` - A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia	Phase 2
Active, not recruiting	`NCT03989947` - An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia	Phase 2
Active, not recruiting	`NCT05246033` - A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia	Phase 2

NCT number	NCT05353192
Study type	Interventional
Source	GeneScience Pharmaceuticals Co., Ltd.
Contact	Yanru Wu
Phone	+86 15843110489
Email	wuyanru@gensci-china.com
Status	Recruiting
Phase	Phase 4
Start date	September 23, 2022
Completion date	February 2025

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms